Publicaciones científicas

A retrospective chart review study describing metastatic melanoma patients profile and treatment patterns in Spain

21-ago-2019 | Revista: Clinical & Translational Oncology

Márquez-Rodas I (1,2), Arance A (3), Berrocal A (4), Larios CL (5), Curto-García J (5), Campos-Tapias IX (6), Blanca AB (6), Martin-Algarra S (7).

(1) Medical Oncology, Hospital General Universitario Gregorio Marañón, Calle Dr. Esquerdo 46, 28007, Madrid, Spain.
(2) CIBERONC, Madrid, Spain.
(3) Medical Oncology, Hospital Clínic Barcelona, Barcelona, Spain.
(4) Medical Oncology, Hospital General Universitario de Valencia, Valencia, Spain.
(5) Clinical Research Department, MFAR S.L, Barcelona, Spain.
(6) AMGEN S.A, Barcelona, Spain.
(7) Medical Oncology, Clínica Universidad de Navarra, Pamplona, Spain.


To describe patient characteristics by disease stage, resectability status and current treatment management after first diagnosis of IIIB to IV1c advanced (AM)/metastatic melanoma (MM).


Multicentre, retrospective study based on data from medical charts of patients > 18 years at MM first diagnosis, visited by oncologists at 4 reference centres in Spain: Hospital Universitario Gregorio Marañón (Madrid), Hospital General de Valencia (Valencia), Clínica Universidad de Navarra (Pamplona), and Hospital Clínic (Barcelona).


Metastatic non-visceral melanoma (IIIB, IIIC, IV M1a) was reported in 139 (48.6%) patients and 40.9% (n = 117) were diagnosed with IV-M1c disease. 160 (55.9%) metastases were resectable. Available therapies under clinical practice were used in 210 patients; 74 were treated under clinical trials (CT). Intention-to-cure surgery (47.6%) was the most common treatment at time of MM diagnosis. Systemic (45.1% overall) therapy included chemo-, targeted- and immunotherapy (19.6%, 14.3%, 8.4%, respectively). At time of data collection, 26 patients were still alive and 120 had progressed to IV-M1c. Median overall survival (OS) was significantly larger in IIIB patients, 28.9 m (25.2-32.7); the shortest for IV-M1c patients, 11.0 m (8.7-13.3).


Novel treatments are undoubtedly a major step forward in AM/MM, however these are often only available in the CT setting because early stages of development or country-specific regulations. Further prospective studies and multifactorial analysis should be performed to clearly identify possible clinical associations for outcome in Spanish patients with AM/MM.

CITA DEL ARTÍCULO  Clin Transl Oncol. 2019 Aug 21. doi: 10.1007/s12094-019-02201-z.

Nuestros autores